Clinical trials: IBD
Crohn's Disease
Phase II Study of RR110 in Patients With Active Crohn's Disease
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics profile of 1 and 4 mg/kg/day RR110 administrated orally for 8 weeks in patients with active Crohn's disease.
- Trial name
- NCT00417391
- Testing
- RR110 (Tamibarotene)
- Where
- 8 sites in Japan
- Volunteers
- 24 people
- Sponsor
- R&R Inc.
Inflammatory Bowel Diseases, Crohn's Disease
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice.
- Conditions
- Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
- Trial name
- TARGET-IBD (NCT03251118)
- Where
- 37 sites in United States
- Volunteers
- 15,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Ulcerative Colitis
A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC)
A 2-part study, comprising of a 36-week placebo-controlled period (PCP) and a 24-week open-label extension (OLE) period, to assess the efficacy and safety of 2 dose regimens of GB004 when added to background UC therapy of…
- Trial name
- NCT04556383
- Testing
- GB004
- Where
- 77 sites in United States, Georgia and 7 more
- Volunteers
- 236 people
- Sponsor
- GB004, Inc.
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
Tacrolimus Lipid Suspension for Enema in Adult Subjects with Mild to Moderately Active Left-sided/Distal Ulcerative Colitis Who Had an Inadequate Response to the Treatment
The study will evaluate the effectiveness, safety and tolerability of tacrolimus lipid suspension for enema in adult patients with mild to moderately active ulcerative colitis who had an inadequate response or intolerance of at…
- Trial name
- NCT06867042
- Testing
- Tacrolimus Lipid Suspension for enema, Identical Tacrolimus-free Lipid Suspension for Enema
- Volunteers
- 150 people
- Sponsor
- Jina Pharmaceuticals Inc.
Irritable Bowel Syndrome, Irritable Bowel
GutMe!: IBS and Collagen Protein Powder an Interventional Study
In this study we would like to understand how or if a food-based supplement affects gut symptoms such as bloating, stomach cramps and irregular bowel habits.
- Conditions
- Irritable Bowel Syndrome, Irritable Bowel, Irrit
- Trial name
- GutMe (NCT04245254)
- Testing
- Collagen Protien Powder
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- ProofPilot
Crohn Disease, Arthritis, Rheumatoid
Remicade Infusion Management Program
Janssen Inc. plans to collect data on about 3000 to 5000 infliximab infusions per year, starting in the third quarter of 2005. It is expected that about 12 sites from the Remicade Infusion Network (R.I.N.) will participate.
- Trial name
- RemiTRAC (NCT00723905)
- Where
- 2 sites in Canada
- Volunteers
- 1,630 people
- Sponsor
- Janssen Inc.
Irritable Bowel Syndrome With Constipation
A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation
The purpose of this study is to evaluate the safety and efficacy of linaclotide for the treatment of Irritable Bowel syndrome with Constipation (IBS-C), in children age 7-17 years.
- Trial name
- LIN-MD-63 (NCT02559817)
- Testing
- Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C
- Where
- 48 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- Forest Laboratories
Colitis, Ulcerative
A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis
The purpose of this real world non-interventional study is to learn about the effects of etrasimod as treatment for patients with moderate to severe ulcerative colitis.
- Trial name
- EFFECT-UC (NCT06294925)
- Testing
- Etrasimod
- Where
- 41 sites in Canada, Germany and 1 more
- Volunteers
- 360 people
- Sponsor
- Pfizer
Ulcerative Colitis
A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis
The study proposes to assess whether compared to placebo, CP-690,550 is effective, safe, and tolerable maintenance therapy in subjects with Ulcerative Colitis (UC).
- Trial name
- OCTAVE (NCT01458574)
- Testing
- CP690,550, CP-690,550
- Where
- 275 sites in United States, Australia and 29 more
- Volunteers
- 593 people
- Sponsor
- Pfizer
Crohn's Disease
High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease
The purpose of this 4 week study is to determine whether PASER®, an approved delayed-release oral formulation of 4-aminosalicylic acid, in doses of 4 grams three times daily for 2 weeks followed by 4 grams twice daily for 2…
- Trial name
- NCT00417690
- Testing
- 4-Aminosalicylic acid
- Where
- 5 sites in United States, Israel
- Volunteers
- 54 people
- Sponsor
- Jacobus Pharmaceutical
Ulcerative Colitis (UC)
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.
- Trial name
- LEGACY (NCT01848561)
- Where
- 512 sites in United States, Australia and 19 more
- Volunteers
- 8,250 people
- Sponsor
- AbbVie
Irritable Bowel Syndrome
Effect of Probiotic Supplement in Alleviating Functional Gastrointestinal Symptoms
The purpose of this study is to analyse the effect of a probiotic supplement on functional intestinal symptoms among subjects diagnosed with irritable bowel syndrome (IBS).
- Trial name
- NCT01728610
- Testing
- Probiotic (Active high), Probiotic (Active low)
- Where
- 2 sites in Finland
- Volunteers
- 391 people, healthy volunteers welcome
- Sponsor
- Danisco
Colitis, Ulcerative
Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)
The purpose of this study is to prove the therapeutic equivalence and safety of once-daily 9 mg budesonide versus 3 g mesalazine in a 8-week treatment in patients with active ulcerative colitis.
- Trial name
- NCT00747110
- Testing
- budesonide, mesalazine
- Where
- Germany
- Volunteers
- 343 people
- Sponsor
- Dr. Falk Pharma GmbH
IBS - Irritable Bowel Syndrome, Inflammation
Study of Inflammatory Markers and Symptom Severity in Personalized Nutritional Intervention in IBS
Irritable Bowel Syndrome (IBS) is a widespread disease with variable symptoms that have an important impact on the quality of life.
- Trial name
- NCT04348760
- Testing
- Rotation Diet
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- GEK Srl
Ulcerative Colitis
Safety, Tolerability and Pharmacokinetics of Oral NX-13 in Healthy Adults Male and Female Volunteers
This is a randomized, double-blind, placebo-controlled, ascending dose, multi-cohort study. The study will be conducted in 2 parts: a single ascending dose (SAD) part (Part A) followed by a multiple ascending dose (MAD) part…
- Trial name
- NCT04458805
- Testing
- NX-13 250 mg
- Where
- Australia
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Landos Biopharma Inc.
Ulcerative Colitis
A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.
The hypothesis of the study is that at least one dose of CP 690 550 is superior to placebo (inactive drug) in inducing remission in patients with moderate to severe ulcerative colitis.
- Trial name
- NCT00787202
- Testing
- CP- 690 550
- Where
- 59 sites in Belgium, Brazil and 15 more
- Volunteers
- 195 people
- Sponsor
- Pfizer
Ulcerative Colitis (UC)
Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis
The purpose of this phase III, multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of Hemay005 compared to placebo as induction and maintenance therapy in Chinese participants with…
- Trial name
- NCT07650942
- Testing
- Hemay005 tablet
- Where
- 2 sites in China
- Volunteers
- 360 people
- Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
Crohn's Disease
Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease
The purpose of this study is to determine the safety and tolerability of natalizumab in adolescents (ages 12-17) diagnosed with moderately to severely active Crohn's disease (CD).
- Trial name
- NCT00055367
- Testing
- natalizumab
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Biogen
Crohn's Disease
Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease
The current study is designed to measure the corticosteroid-sparing effect of certolizumab pegol using a defined schedule of corticosteroid tapering in subjects with moderate to severe Crohn's disease.
- Trial name
- COSPAR1 (NCT00349752)
- Testing
- certolizumab pegol 400 mg
- Where
- 68 sites in United States, Canada and 1 more
- Volunteers
- 174 people
- Sponsor
- UCB Pharma
Ulcerative Colitis
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to < 18 years of age).
- Trial name
- NCT05287126
- Testing
- Etrasimod
- Where
- 47 sites in United States, Japan and 3 more
- Volunteers
- 36 people
- Sponsor
- Pfizer